Reply  by Giles, Kristina A. et al.
LETTERS TO THE EDITOR
W
D
D
D
L
D
D
D
M
D
D
D
M
D
D
D
R
1
2
d
R
l
b
w
s
f
d
c
s
d
g
a
T
c
s
m
b
p
c
n
s
cRegarding “Stroke and death after carotid
endarterectomy and carotid artery stenting with and
without high risk criteria”
In a recent article byGiles et al,1 the authors report higher risks
of stroke, death, and a composite end point of stroke or death
among patients undergoing carotid artery stenting (CAS) com-
pared with carotid endarterectomy (CEA). We are concerned that
the results of the study likely reflect substantial unmeasured con-
founding rather than a true difference in outcomes between the
cohorts.
Limitations of the administrative data source regarding clinical
indication are apparent when considered in the context of the
existingMedicare national coverage decision for patients undergo-
ing CAS with embolic protection, defined as follows:
1. patients who are at high risk for CEA and have symptomatic
carotid artery stenosis 70%;
2. patients who are at high risk for CEA and have symptomatic
carotid artery stenosis between 50% and 70%, in accordance
with the category B investigational device exemption; and
3. patients who are at high risk for CEA and have asymptomatic
carotid artery stenosis80%, in accordance with the category B
investigational device exemption.
High-risk features were defined as congestive heart failure
New York Heart Association functional class III/IV, left ventric-
ular ejection fraction 30%, unstable angina, contralateral carotid
occlusion, recent myocardial infarction, previous CEA with recur-
rent stenosis, prior radiation treatment to the neck, and other
conditions that were used to determine patients at high risk for
CEA in prior CAS trials.
Given these criteria, one would expect event rates with CAS to
be higher than event rates with CEA because, by definition, the
eligible population for CAS is at higher risk. The similarities
between patients who underwent CAS and patients who under-
went CEA calls into question the validity of the data, not the
relative effectiveness of the interventions.
In contrast, the categorization of high-risk vs non–high-risk
patients did not affect the observed mortality rate in the overall
CAS group (1.5% in both groups). The mortality rate was margin-
ally higher among patients with asymptomatic CAS deemed non–
high-risk compared with high-risk (0.9% vs 0.7%). These findings
again call into question the categorization of high risk in the CAS
group, a definition in this study that depended on inpatient diag-
nosis and billing codes that, to our knowledge, are poorly vali-
dated.
Finally, data from several randomized trials provide important
information. In Carotid Revascularization Endarterectomy vs
Stent Trial (CREST),2 for example, the composite end point was
not different between the CAS and CEA groups; however, minor
stroke rates were higher for patients undergoing CAS and myocar-
dial infarction rates were higher for patients undergoing CEA.
None of the available data have identified a mortality difference. In
fact, the current Medicare coverage rule for patients who are
undergoing CAS and are enrolled in clinical trials (two of the three
approved indications) likely introduces ascertainment bias among
patients who undergo routine mandated stroke evaluations by
independent neurologists.
We appreciate the limitations noted by the authors, but we
have serious concerns that the adjusted comparisons suffer from
unmeasured confounding. The presentation of observed outcomes
is helpful for clinicians and patients, but appropriate interpretation
for health care policy makers requires judicious consideration of
these issues.
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Although we agree that the database used for this study has
imitations related to the identification of comorbidities, we do not
elieve that this should negate the findings. In fact, this analysis
as undertaken because we believed that prior analyses of carotid
tenting (CAS) vs endarterectomy (CEA) using this database suf-
ered from potential confounding related to high-risk status. The
efinitions of International Classification of Disease (9th revision)
oding to identify high risk, as we have noted, do overestimate
ome of the criteria.
High-grade congestive heart failure and severe chronic lung
isease are too specific for the coding system; therefore, we used all
rades of congestive heart failure and chronic lung disease. In
ddition, we cannot identify the timing of a prior heart attack.
hese limitations, however, apply to both the CEA and CAS
ohorts.
In acknowledging the limitation of overestimation of high-risk
tatus with the nationwide inpatient sample, perhaps the most
eaningful comparison is the difference in stroke or death rates
etween non–high-risk CAS patients (3.1%) and high-risk CEA
atients (1.8%). Another key finding is that high-risk status in-
reases the risk of adverse events for both CEA and CAS.
We believe that this study shows that national outcomes are
ot necessarily reflected by tightly controlled trials and that patient
election is of critical importance when considering carotid revas-
ularization by either method. We agree that decisions regarding
ealth care policy should be made with careful attention to study
nd data limitations for all published literature.
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Regarding the Commentary for “Novel sutureless
telescoping anastomosis revascularization technique
of supra-aortic vessels to simplify combined open
endovascular procedures in the treatment of aortic
arch pathologies”
We thank Dr Ballard for his comments. Although skepticism
can be a good thing, we might remind him that such skepticism
greeted innovative disruptive technologies like balloon angioplasty
and endovascular aneurysm repair. While our technique may not
be as important as these procedures, we believe it does provide a
simpler, safer way of performing aortic branch anastomoses, par-
ticularly in adverse circumstances. As such it should be helpful to
vascular surgeons and at least deserves their attention and evalua-
tion.
Our method offers major advantages in terms of substantially
reducing the need for vessel dissection and end organ ischemia.
Even if some cannot reproduce our short anastomotic times ex-
actly, they were accurate for our group and could be duplicated by
a number of our trainees and visiting vascular surgeons who
learned them easily.
We do believe these techniques will be helpful to vascular
surgeons and their patients, and represent a better way of perform-
ing anastomoses, especially in challenging conditions. We hope
many others will be interested in using our technique, and we look
forward to reports from them that they have found it useful.
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Regarding “Aneurysmal iliac arteries do not portend
future iliac aneurysmal enlargement after
endovascular aneurysm repair for abdominal aortic
aneurysm”
We would agree with the authors1 that aneurysmal degenera-
tion of the iliac arteries does not occur in either normal or ectactic drteries at the time of endovascular aneurysm repair (EVAR), but
nly up to 5 years postendovascular repair.
We have previously shown2-4 that up to 5 years after EVAR,
neurysmal dilatation does not take place. However, between 5
nd 12 years, there is a low (3%) but definite incidence of
neurysmal dilatation. We too reported that aneurysmal dilatation
ccurred in arteries of 20-mm diameter. We also reported that
he aneurysm formation occurred in arteries, which were the
anding site of EVAR, as well as in iliacs that were contralateral to
he uni-iliac landing site in that type of reconstruction.
We note that the above study ran to only 5 years after EVAR.We
ould expect a similar incidence of aneurysmal degeneration in the
liacs in this study after 5 years in survivors with intact endografts.
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We appreciate the letter by Dr Mohan Adiseshiah. It ad-
resses a limitation of our study in that our follow-up is limited
o those data which are collected on the Zenith clinical trial. It
ertainly would be interesting to see if we had similar results out
o 12 years or if the iliac arteries remained stable. Unfortunately,
hose data are not available.
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